About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

An Extension Study for Patients Previously Treated With ARQ 501

NCT00622063·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Signed written informed consent
Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment

You may not be if

Have not received previous treatment with ARQ 501 under a treatment protocol
Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

The record

StatusCompleted

PhasePhase 1–2

Taking part1

StartedDec 2006

UpdatedFeb 28, 2013

Conditions

Where1

Mary Crowley Medical Research Center
Dallas, Texas, United States

Clareo Health | An Extension Study for Patients Previously Treated With ARQ 501